![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » STRATAGENE SAYS JURY DETERMINED THAT INVITROGEN'S 4,981,797 PATENT IS VALID
STRATAGENE SAYS JURY DETERMINED THAT INVITROGEN'S 4,981,797 PATENT IS VALID
July 26, 2006
Stratagene Corp. said the jury determined that Invitrogen Corp.'s 4,981,797 patent is valid and that Stratagene infringed that patent by making and selling its competent E. coli cell products. Stratagene
has the option to the verdict. The action by Invitrogen was initiated in March
2001.
Trading
Markets
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct